NCT04894721 (IVERNEX-TUC) is a Phase 2, PHASE3 clinical trial of Ivermectin in Covid19, sponsored by Ministry of Public Health, Argentina.

Who is sponsoring NCT04894721?

NCT04894721 is sponsored by Ministry of Public Health, Argentina.

What drugs are being tested in NCT04894721?

Interventions in NCT04894721: Ivermectin, Placebo.

Is NCT04894721 still recruiting?

NCT04894721 is currently completed. Last updated 7 December 2021.

Last reviewed 2021-12-07 · How we verify

NCT04894721: IVERNEX-TUC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC)

Completed Phase 2, PHASE3 Last updated 7 December 2021

What this trial tests

Phase 2, PHASE3 trial testing Ivermectin in Covid19 in 172 participants. Completed in 1 October 2021.

Timeline

1 June 2021

Primary endpoint
30 September 2021

1 October 2021

Quick facts

Lead sponsor	Ministry of Public Health, Argentina
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	172
Start date	1 June 2021
Primary completion	30 September 2021
Estimated completion	1 October 2021
Sites	1 location across Argentina

Drugs / interventions tested

Ivermectin (ivermectin) — full drug profile →
Placebo

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Ministry of Public Health, Argentina

Who can join

Adults 18 to 60, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized controlled clinical trial on using oral ivermectin in COVID-19 prophylaxis supplying the drug to close contacts of confirmed cases.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Ivermectin for preventing and treating COVID-19.
Popp M, Stegemann M, Metzendorf MI, Gould S, et al · · 2021 · cited 102× · PMID 34318930 · DOI 10.1002/14651858.cd015017.pub2
Ivermectin for preventing and treating COVID-19.
Popp M, Reis S, Schießer S, Hausinger RI, et al · · 2022 · cited 30× · PMID 35726131 · DOI 10.1002/14651858.cd015017.pub3
Potential Prophylactic Treatments for COVID-19.
Ben-Zuk N, Dechtman ID, Henn I, Weiss L, et al · · 2021 · cited 9× · PMID 34372498 · DOI 10.3390/v13071292

Verify or expand the search:

Other trials of Ivermectin

Trials testing the same drug.

NCT07396714 — the Efficacy of Ivermectin Alone or With Microneedling in Treatment of Cutaneous Warts. · EARLY_PHASE1 · not yet recruiting
NCT07145736 — Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical · Phase 4 · recruiting
NCT05605925 — Ivermectin-artemisinin Combination Therapy for Eradication of Malaria · Phase 4 · unknown
NCT05045937 — Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19 · unknown
NCT05643820 — Comparison of Oral Ivermectin and Permethrin 5% Lotion in Treatment of Pediculosis Capitis · Phase 1 · completed

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Ministry of Public Health, Argentina trials

Trials by the same sponsor.

NCT05644145 — Immunogenicity of Yellow Fever Vaccine in a Pediatric Population Vaccinated at 12-23 Months of Age in Argentina · NA · active not recruiting
NCT04988048 — Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina · Phase 2 · unknown
NCT04784481 — Ivermectin Reproposing for Mild Stage COVID-19 Outpatients · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04894721 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ministry of Public Health, Argentina
Last refreshed: 7 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04894721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing